1 – 10 of 188
      - show: 10
 - |
 - sort: year (new to old)
 
        Close
        
            
    
    Embed this list
<iframe src=""
              width=""
              height=""
              allowtransparency="true"
              frameborder="0">
            </iframe>
        - 2025
 - 
                        Mark
        Comorbidity and Mortality in Men and Women With Haemophilia in Three Nordic Countries–Comparisons to Matched Controls
    
    
- Contribution to journal › Article
 
 - 
                        Mark
        A plain language summary on indirectly comparing bleeding after valoctocogene roxaparvovec gene therapy to bleeding with emicizumab prophylaxis
    
    
- Contribution to journal › Article
 
 - 2024
 - 
                        Mark
        Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B) : 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
    
    
- Contribution to journal › Article
 
 - 
                        Mark
        Low bleeding rates after intramuscular Covid-19 vaccination in patients with haemophilia and von Willebrand disease : Outcome data from the Swedish haemophilia registry
    
    
- Contribution to journal › Debate/Note/Editorial
 
 - 
                        Mark
        Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients
    
    
- Contribution to journal › Article
 
 - 
                        Mark
        Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
    
    
- Contribution to journal › Article
 
 - 
                        Mark
        Future needs for continuing innovation in hemophilia : improving outcomes for individuals of all severities, including women and those in resource-constrained regions
    
    
- Contribution to journal › Scientific review
 
 - 
                        Mark
        Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8) : a prospective, multicentre, open-label, randomised, phase 3a trial
    
    
- Contribution to journal › Article
 
 - 
                        Mark
        Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.
    
    
- Contribution to journal › Article
 
 - 
                        Mark
        Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study)
    
    
- Contribution to journal › Article
 
 
